FDA Debates The “Slowdown”: Temple Sees No Sign Of Excess Caution
Executive Summary
An analysis of recent drug approvals that took longer than one year shows no indications of a more conservative attitude by FDA, Office of Medical Policy Director Robert Temple, MD, told the Food & Drug Law Institute conference April 17 in Washington, D.C
You may also be interested in...
NME Approval Decline Likely To Continue In 2002: Only Two Filed This Year
FDA has received only two NDAs for new molecular entities so far in 2002, Office of New Drugs Director John Jenkins, MD, told UBS Warburg's specialty pharma conference in New York City June 6
NME Approval Decline Likely To Continue In 2002: Only Two Filed This Year
FDA has received only two NDAs for new molecular entities so far in 2002, Office of New Drugs Director John Jenkins, MD, told UBS Warburg's specialty pharma conference in New York City June 6
FDA Restricted Distribution Rulemaking May Clarify Regulatory Issues
FDA may consider a formal rulemaking on the use of restricted distribution programs